GH
Guardant Health, Inc.
Price Chart
Latest Quote
$130.83
+2.00 (+1.55%)
Current Price
| Previous Close | $128.83 |
| Open | $128.67 |
| Day High | $134.75 |
| Day Low | $127.61 |
| Volume | 1,896,446 |
Stock Information
| Shares Outstanding | 132.60M |
| Total Debt | $1.70B |
| Cash Equivalents | $1.10B |
| Revenue | $1.08B |
| Net Income | $-433.19M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $17.35B |
| EPS (TTM) | $-3.40 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $17.95B |
| Sales | $1.08B |
| Income | $-433.19M |
| Book/sh | $-1.38 |
| Cash/sh | $8.32 |
| Employees | 2K |
Financial Ratios
| Quick Ratio | 4.25 |
| Current Ratio | 4.68 |
Returns & Margins
| ROA | -17.15% |
| Gross Margin | 64.90% |
| Operating Margin | -40.23% |
| Profit Margin | -40.10% |
Ownership
| Insider Ownership | 4.03% |
| Institutional Ownership | 106.03% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -275.59 |
| P/S | 16.06 |
| P/B | -95.01 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $143.09 |
Technical Indicators
| SMA20 | $129.06 |
| SMA50 | $107.67 |
| SMA200 | $94.58 |
| RSI | 50.87 |
| ATR | 6.3204 |
| Shares Float | 127.93M |
| Short Float | 10.38% |
| Short Ratio | 5.54 |
| Volatility | 1.62 |
| Rel Volume | 0.82 |
Performance History
| Week | +0.78% |
| Month | +10.86% |
| Quarter | +53.99% |
| 6 Months | +34.74% |
| YTD | +28.59% |
| Year | +166.24% |
| 3 Years | +245.56% |
| 5 Years | +11.16% |
| 10 Years | +306.30% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $130.83 | 1,896,446 |
| 2026-06-22 | $128.83 | 1,444,300 |
| 2026-06-18 | $131.78 | 3,408,800 |
| 2026-06-17 | $129.11 | 2,118,900 |
| 2026-06-16 | $127.34 | 2,672,300 |
| 2026-06-15 | $129.82 | 1,649,000 |
| 2026-06-12 | $131.62 | 1,511,200 |
| 2026-06-11 | $130.90 | 1,502,600 |
| 2026-06-10 | $130.70 | 1,797,500 |
| 2026-06-09 | $130.12 | 2,258,300 |
| 2026-06-08 | $124.89 | 2,213,900 |
| 2026-06-05 | $125.61 | 3,345,400 |
| 2026-06-04 | $133.06 | 2,014,300 |
| 2026-06-03 | $127.03 | 2,111,500 |
| 2026-06-02 | $130.17 | 2,088,900 |
| 2026-06-01 | $129.14 | 2,414,000 |
| 2026-05-29 | $129.69 | 3,513,800 |
| 2026-05-28 | $133.22 | 2,997,100 |
| 2026-05-27 | $127.51 | 3,407,800 |
| 2026-05-26 | $119.85 | 1,982,300 |
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
đ° Latest News
Dow Jones Futures Rise As Kospi Index Rebounds; FedEx, Cerebras Tumble Late With Micron Due
Investor's Business Daily âĸ 2026-06-24T02:19:02Z
3 Russell 2000 Stocks We Approach with Caution
StockStory âĸ 2026-06-22T13:47:19Z
Living Longer Is Big Business. These Stocks Will Benefit.
Barrons.com âĸ 2026-06-18T18:14:00Z
How The Guardant Health (GH) Investment Story Is Evolving As Expectations Stay Unchanged
Simply Wall St. âĸ 2026-06-05T19:12:23Z
Tesla upgraded, Lululemon downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-06-05T13:36:13Z
1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds
StockStory âĸ 2026-06-05T13:12:14Z
A new blood test can help detect colon cancer, but itâs not as good as the test you hate to take
MarketWatch âĸ 2026-06-05T11:51:00Z
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
StockStory âĸ 2026-06-04T17:01:30Z
Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favorite
Investor's Business Daily âĸ 2026-06-04T16:10:02Z
Here Are Tuesdayâs Top Wall Street Analyst Research Calls: CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, Tripadvisor, and More
24/7 Wall St. âĸ 2026-06-02T12:11:52Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $349,007,000 | $289,799,000 | $227,052,000 | $156,325,000 |
| Cost Of Revenue | $349,007,000 | $289,799,000 | $227,052,000 | $156,325,000 |
| Total Revenue | $982,021,000 | $739,016,000 | $563,948,000 | $449,538,000 |
| Operating Revenue | $982,021,000 | $739,016,000 | $563,948,000 | $449,538,000 |
| Expenses | ||||
| Interest Expense | $3,897,000 | $2,581,000 | $2,578,000 | $2,577,000 |
| Total Expenses | $1,419,269,000 | $1,182,610,000 | $1,128,673,000 | $993,916,000 |
| Other Income Expense | $-10,490,000 | $-42,605,000 | $53,174,000 | $-112,563,000 |
| Other Non Operating Income Expenses | $-10,490,000 | $-42,605,000 | $53,174,000 | $-112,563,000 |
| Net Non Operating Interest Income Expense | $30,198,000 | $51,110,000 | $32,787,000 | $3,492,000 |
| Interest Expense Non Operating | $3,897,000 | $2,581,000 | $2,578,000 | $2,577,000 |
| Operating Expense | $1,070,262,000 | $892,811,000 | $901,621,000 | $837,591,000 |
| Selling And Marketing Expense | $494,661,000 | $364,935,000 | $295,227,000 | $299,828,000 |
| General And Administrative Expense | $211,410,000 | $180,123,000 | $155,800,000 | $163,956,000 |
| Other Operating Expenses | - | - | $83,400,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-416,277,000 | $-436,373,000 | $-479,449,000 | $-654,588,000 |
| Net Interest Income | $30,198,000 | $51,110,000 | $32,787,000 | $3,492,000 |
| Interest Income | $34,095,000 | $53,691,000 | $35,365,000 | $6,069,000 |
| Normalized Income | $-416,277,000 | $-436,373,000 | $-479,449,000 | $-654,588,000 |
| Net Income From Continuing And Discontinued Operation | $-416,277,000 | $-436,373,000 | $-479,449,000 | $-654,588,000 |
| Total Operating Income As Reported | $-437,248,000 | $-443,594,000 | $-564,725,000 | $-544,378,000 |
| Net Income Common Stockholders | $-416,277,000 | $-436,373,000 | $-479,449,000 | $-654,588,000 |
| Net Income | $-416,277,000 | $-436,373,000 | $-479,449,000 | $-654,588,000 |
| Net Income Including Noncontrolling Interests | $-416,277,000 | $-436,373,000 | $-479,449,000 | $-654,588,000 |
| Net Income Continuous Operations | $-416,277,000 | $-436,373,000 | $-479,449,000 | $-654,588,000 |
| Pretax Income | $-417,540,000 | $-435,089,000 | $-478,764,000 | $-653,449,000 |
| Interest Income Non Operating | $34,095,000 | $53,691,000 | $35,365,000 | $6,069,000 |
| Operating Income | $-437,248,000 | $-443,594,000 | $-564,725,000 | $-544,378,000 |
| Gross Profit | $633,014,000 | $449,217,000 | $336,896,000 | $293,213,000 |
| Per Share | ||||
| Diluted EPS | $-3.32 | $-3.56 | $-4.28 | $-6.41 |
| Basic EPS | $-3.32 | $-3.56 | $-4.28 | $-6.41 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-373,907,000 | $-390,121,000 | $-433,305,000 | $-614,910,000 |
| Reconciled Depreciation | $39,736,000 | $42,387,000 | $42,881,000 | $35,962,000 |
| EBITDA (Bullshit earnings) | $-373,907,000 | $-390,121,000 | $-433,305,000 | $-614,910,000 |
| EBIT | $-413,643,000 | $-432,508,000 | $-476,186,000 | $-650,872,000 |
| Diluted Average Shares | $125,374,000 | $122,745,000 | $111,988,000 | $102,178,000 |
| Basic Average Shares | $125,374,000 | $122,745,000 | $111,988,000 | $102,178,000 |
| Diluted NI Availto Com Stockholders | $-416,277,000 | $-436,373,000 | $-479,449,000 | $-654,588,000 |
| Tax Provision | $-1,263,000 | $1,284,000 | $685,000 | $1,139,000 |
| Research And Development | $364,191,000 | $347,753,000 | $367,194,000 | $373,807,000 |
| Selling General And Administration | $706,071,000 | $545,058,000 | $451,027,000 | $463,784,000 |
| Other Gand A | $211,410,000 | $180,123,000 | $155,800,000 | $163,956,000 |
| Minority Interests | - | - | $0 | $0 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-202,485,000 | $-149,697,000 | $146,415,000 | $45,163,000 |
| Total Assets | $2,013,659,000 | $1,485,609,000 | $1,786,421,000 | $1,609,985,000 |
| Total Non Current Assets | $547,613,000 | $430,495,000 | $439,315,000 | $418,391,000 |
| Other Non Current Assets | $139,671,000 | $141,367,000 | $124,334,000 | $61,453,000 |
| Goodwill And Other Intangible Assets | $103,178,000 | $10,050,000 | $12,269,000 | $15,017,000 |
| Other Intangible Assets | $25,921,000 | $6,760,000 | $8,979,000 | $11,727,000 |
| Current Assets | $1,466,046,000 | $1,055,114,000 | $1,347,106,000 | $1,191,594,000 |
| Other Current Assets | $40,723,000 | $33,800,000 | $27,741,000 | $31,509,000 |
| Inventory | $85,876,000 | $71,083,000 | $61,948,000 | $51,598,000 |
| Receivables | $137,849,000 | $110,253,000 | $88,783,000 | $97,256,000 |
| Other Receivables | $5,200,000 | $3,400,000 | $4,900,000 | - |
| Accounts Receivable | $132,649,000 | $106,853,000 | $83,883,000 | $97,256,000 |
| Cash Cash Equivalents And Short Term Investments | $1,201,598,000 | $839,978,000 | $1,168,634,000 | $1,011,231,000 |
| Cash And Cash Equivalents | $378,203,000 | $525,540,000 | $1,133,537,000 | $141,647,000 |
| Investmentin Financial Assets | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $1,125,797,000 | $617,007,000 | $6,429,000 | $995,744,000 |
| Total Debt | $1,710,142,000 | $1,336,052,000 | $1,353,764,000 | $1,369,284,000 |
| Long Term Debt And Capital Lease Obligation | $1,682,463,000 | $1,306,839,000 | $1,325,814,000 | $1,347,406,000 |
| Long Term Debt | $1,504,000,000 | $1,142,547,000 | $1,139,966,000 | $1,137,391,000 |
| Current Debt And Capital Lease Obligation | $27,679,000 | $29,213,000 | $27,950,000 | $21,878,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,112,966,000 | $1,625,256,000 | $1,627,737,000 | $1,549,805,000 |
| Total Non Current Liabilities Net Minority Interest | $1,810,236,000 | $1,399,673,000 | $1,421,820,000 | $1,356,585,000 |
| Other Non Current Liabilities | $127,773,000 | $92,834,000 | $96,006,000 | $9,179,000 |
| Current Liabilities | $302,730,000 | $225,583,000 | $205,917,000 | $193,220,000 |
| Current Deferred Liabilities | $50,753,000 | $35,468,000 | $17,965,000 | $17,403,000 |
| Payables And Accrued Expenses | $104,652,000 | $77,683,000 | $87,266,000 | $98,151,000 |
| Payables | $54,442,000 | $38,551,000 | $51,741,000 | $68,911,000 |
| Accounts Payable | $54,442,000 | $38,551,000 | $51,741,000 | $68,911,000 |
| Other Payable | - | - | - | $29,240,000 |
| Other Current Liabilities | - | - | - | - |
| Total Tax Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $-99,307,000 | $-139,647,000 | $158,684,000 | $60,180,000 |
| Total Equity Gross Minority Interest | $-99,307,000 | $-139,647,000 | $158,684,000 | $60,180,000 |
| Stockholders Equity | $-99,307,000 | $-139,647,000 | $158,684,000 | $60,180,000 |
| Gains Losses Not Affecting Retained Earnings | $-4,852,000 | $-5,201,000 | $-3,675,000 | $-19,522,000 |
| Other Equity Adjustments | $-4,852,000 | $-5,201,000 | $-3,675,000 | $-19,522,000 |
| Retained Earnings | $-2,994,512,000 | $-2,578,235,000 | $-2,141,862,000 | $-1,662,413,000 |
| Other | ||||
| Treasury Shares Number | $0 | - | - | - |
| Ordinary Shares Number | $130,635,301 | $123,994,006 | $121,629,861 | $102,619,383 |
| Share Issued | $130,635,301 | $123,994,006 | $121,629,861 | $102,619,383 |
| Tangible Book Value | $-202,485,000 | $-149,697,000 | $146,415,000 | $45,163,000 |
| Invested Capital | $1,404,693,000 | $1,002,900,000 | $1,298,650,000 | $1,197,571,000 |
| Working Capital | $1,163,316,000 | $829,531,000 | $1,141,189,000 | $998,374,000 |
| Capital Lease Obligations | $206,142,000 | $193,505,000 | $213,798,000 | $231,893,000 |
| Total Capitalization | $1,404,693,000 | $1,002,900,000 | $1,298,650,000 | $1,197,571,000 |
| Additional Paid In Capital | $2,900,056,000 | $2,443,788,000 | $2,304,220,000 | $1,742,114,000 |
| Capital Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Common Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $178,463,000 | $164,292,000 | $185,848,000 | $210,015,000 |
| Current Deferred Revenue | $50,753,000 | $35,468,000 | $17,965,000 | $17,403,000 |
| Current Capital Lease Obligation | $27,679,000 | $29,213,000 | $27,950,000 | $21,878,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $119,646,000 | $83,219,000 | $72,736,000 | $55,788,000 |
| Current Accrued Expenses | $50,210,000 | $39,132,000 | $35,525,000 | $29,240,000 |
| Goodwill | $77,257,000 | $3,290,000 | $3,290,000 | $3,290,000 |
| Net PPE | $304,764,000 | $279,078,000 | $302,712,000 | $341,921,000 |
| Accumulated Depreciation | $-198,901,000 | $-165,525,000 | $-127,308,000 | $-88,131,000 |
| Gross PPE | $503,665,000 | $444,603,000 | $430,020,000 | $430,052,000 |
| Leases | $107,696,000 | $103,569,000 | $102,298,000 | $99,781,000 |
| Construction In Progress | $41,252,000 | $28,136,000 | $7,508,000 | $20,598,000 |
| Other Properties | $158,849,000 | $142,265,000 | $157,616,000 | $174,001,000 |
| Machinery Furniture Equipment | $195,868,000 | $170,633,000 | $162,598,000 | $135,672,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $823,395,000 | $314,438,000 | $35,097,000 | $869,584,000 |
| Investments And Advances | - | - | - | $0 |
| Minority Interest | - | - | - | - |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-233,066,000 | $-274,943,000 | $-345,461,000 | $-386,924,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-184,760,000 | $-239,858,000 | $-324,975,000 | $-309,463,000 |
| Cash Flow From Continuing Operating Activities | $-184,760,000 | $-239,858,000 | $-324,975,000 | $-309,463,000 |
| Operating Gains Losses | $-13,672,000 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-48,306,000 | $-35,085,000 | $-20,486,000 | $-77,461,000 |
| Investing Cash Flow | $-627,202,000 | $-261,308,000 | $840,250,000 | $149,816,000 |
| Cash Flow From Continuing Investing Activities | $-627,202,000 | $-261,308,000 | $840,250,000 | $149,816,000 |
| Net Other Investing Changes | - | - | $1,531,000 | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-45,010,000 | $0 | $0 | - |
| Issuance Of Capital Stock | $345,000,000 | $0 | $493,116,000 | $0 |
| Financing Cash Flow | $671,133,000 | $-996,000 | $477,375,000 | $-189,093,000 |
| Cash Flow From Continuing Financing Activities | $671,133,000 | $-996,000 | $477,375,000 | $-189,093,000 |
| Net Other Financing Charges | $-64,165,000 | $-15,834,000 | $-26,300,000 | $-201,034,000 |
| Net Common Stock Issuance | $299,990,000 | $0 | $493,116,000 | $0 |
| Common Stock Issuance | $345,000,000 | $0 | $493,116,000 | $0 |
| Other | ||||
| Issuance Of Debt | $402,500,000 | $0 | $0 | $0 |
| Interest Paid Supplemental Data | $3,771,000 | $0 | $0 | - |
| Income Tax Paid Supplemental Data | $869,000 | $1,007,000 | $1,969,000 | $1,331,000 |
| End Cash Position | $489,417,000 | $629,755,000 | $1,133,687,000 | $141,948,000 |
| Beginning Cash Position | $629,755,000 | $1,133,687,000 | $141,948,000 | $492,288,000 |
| Effect Of Exchange Rate Changes | $491,000 | $-1,770,000 | $-911,000 | $-1,600,000 |
| Changes In Cash | $-140,829,000 | $-502,162,000 | $992,650,000 | $-348,740,000 |
| Proceeds From Stock Option Exercised | $32,808,000 | $14,838,000 | $10,559,000 | $11,941,000 |
| Common Stock Payments | $-45,010,000 | $0 | $0 | - |
| Net Issuance Payments Of Debt | $402,500,000 | $0 | $0 | $-71,000 |
| Net Long Term Debt Issuance | $402,500,000 | $0 | $0 | $-71,000 |
| Long Term Debt Issuance | $402,500,000 | $0 | $0 | $0 |
| Net Investment Purchase And Sale | $-519,908,000 | $-226,223,000 | $860,736,000 | $227,277,000 |
| Sale Of Investment | $307,323,000 | $88,600,000 | $1,496,231,000 | $555,000,000 |
| Purchase Of Investment | $-827,231,000 | $-314,823,000 | $-635,495,000 | $-327,723,000 |
| Net Business Purchase And Sale | $-58,988,000 | $0 | $0 | - |
| Purchase Of Business | $-58,988,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-48,306,000 | $-35,085,000 | $-20,486,000 | $-77,461,000 |
| Purchase Of PPE | $-48,306,000 | $-35,085,000 | $-20,486,000 | $-77,461,000 |
| Change In Working Capital | $-14,429,000 | $-60,862,000 | $53,840,000 | $61,564,000 |
| Change In Other Working Capital | $19,455,000 | $18,663,000 | $85,133,000 | $9,873,000 |
| Change In Other Current Liabilities | $-37,524,000 | $-36,115,000 | $-31,478,000 | $-20,228,000 |
| Change In Other Current Assets | $212,000 | $-2,375,000 | $1,298,000 | $11,698,000 |
| Change In Payables And Accrued Expense | $52,749,000 | $-2,820,000 | $5,191,000 | $60,328,000 |
| Change In Prepaid Assets | $-6,354,000 | $-7,691,000 | $-4,332,000 | $20,444,000 |
| Change In Inventory | $-14,792,000 | $-9,135,000 | $-10,350,000 | $-20,926,000 |
| Change In Receivables | $-28,175,000 | $-21,389,000 | $8,378,000 | $375,000 |
| Changes In Account Receivables | $-28,175,000 | $-21,389,000 | $8,378,000 | $375,000 |
| Other Non Cash Items | $40,960,000 | $36,952,000 | $31,202,000 | $135,265,000 |
| Stock Based Compensation | $166,217,000 | $140,411,000 | $90,759,000 | $94,685,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $44,401,000 | $-79,710,000 | $7,793,000 |
| Asset Impairment Charge | $18,582,000 | $0 | $29,054,000 | $5,261,000 |
| Amortization Of Securities | $-5,877,000 | $-6,774,000 | $-13,552,000 | $4,595,000 |
| Depreciation Amortization Depletion | $39,736,000 | $42,387,000 | $42,881,000 | $35,962,000 |
| Depreciation And Amortization | $39,736,000 | $42,387,000 | $42,881,000 | $35,962,000 |
| Net Income From Continuing Operations | $-416,277,000 | $-436,373,000 | $-479,449,000 | $-654,588,000 |
| Repayment Of Debt | - | - | - | $-71,000 |
| Long Term Debt Payments | - | - | - | $-71,000 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
| Change In Payable | - | - | - | $60,328,000 |
| Change In Account Payable | - | - | - | $60,328,000 |
| Change In Accrued Expense | - | - | - | - |
| Deferred Tax | - | - | - | - |
| Deferred Income Tax | - | - | - | - |
| Net Foreign Currency Exchange Gain Loss | - | - | - | - |
Fetched: 2026-06-22